Push past the expected. This week’s insights spotlight the bold moves shaping early-phase clinical research across LATAM and beyond.
first-in-human · clinical research · FDA
Global Trial Accelerators™
Push past the expected. This week’s insights spotlight the bold moves shaping early-phase clinical research across LATAM, Eastern Europe, and beyond.
Mexico is taking bold steps to accelerate clinical research while reinforcing ethical integrity. A new collaboration between COFEPRIS, ConBioética, and CCINSHAE aims to harmonize regulatory and ethics committee review processes — with an ambitious goal of approving priority clinical trial protocols in as little as 45 days. This move includes standardized formats for informed consent and ethics submissions, along with support for the upcoming NOM-262-SSA1-2024 standard for Good Clinical Practices. Together, these measures enhance transparency, speed, and alignment with international norms — making Mexico a more attractive destination for early-phase studies. https://consultorsalud.com.mx
Recent decisions by the FDA reflect a growing openness to single-arm clinical trial designs, particularly in therapeutic areas where randomized controls are impractical. These approvals signal a shift toward more flexible, risk-adapted regulatory pathways — especially valuable in rare disease indications or high-need populations.
Key Shifts to Watch:
Sponsors willing to rethink study design may find accelerated regulatory paths with fewer barriers — a potential game-changer for first-in-human or early feasibility trials. https://thefdalawblog.com
Does Your Company Need Accelerated First-in-Human Clinical Trial Results? Overcome the complex landscape of first-in-human clinical trials with confidence. Whether you’re advancing Medtech devices, Biopharma therapies, or Radiopharmaceutical innovations, bioaccess® delivers expert solutions to help you succeed.
Schedule Your First-in-Human Trial Consult
Every stage of a medtech company’s growth brings a new kind of capital — and new expectations. From pre-seed funding focused on technical validation to Series B rounds backing clinical execution, understanding the rhythm of fundraising is as critical as the science itself. Investor interest typically shifts from team strength and proof-of-concept in early rounds to regulatory strategy, clinical readiness, and commercial scalability in later stages. Why It Matters: A well-timed fundraising strategy can be just as important as regulatory success. For early-phase innovators, capital alignment often determines who reaches first-in-human — and who gets left on the slide deck. https://blog.zapyrus.com
Consistency across trial sites isn’t just a regulatory box to check — its the foundation of data reliability, patient safety, and trial success. Moving beyond checklists and training certificates, the conversation around clinical trial quality is shifting toward demonstrable competence, operational excellence, and site-level performance.
Standards in Motion:
https://iaocr.com
Bulgarias CRO Balancing Act: A Playbook for Smart Sponsors Bulgaria is quickly becoming a proving ground for sponsors who know how to play both sides of the clinical research equation. By pairing the institutional credibility of public CROs with the speed and responsiveness of private partners, sponsors are navigating feasibility, ethics, and execution with uncommon efficiency.
Insider Tip: The secret isn’t choosing one or the other — its knowing how to orchestrate both. Dual-sector CRO strategies are quietly powering some of the region’s most effective early-phase studies. https://www.bioaccessla.com
A world-first in robotic-assisted cataract surgery has reset expectations around what’s possible in ophthalmic innovation. With AI-powered precision and autonomous movements enhancing surgeon control, this pioneering procedure not only marks a technological leap — it opens a new chapter for medtech validation in surgical settings.
Why It Matters: First-in-human milestones like this signal where the future is headed. For sponsors in early development, its a reminder that clinical readiness isn’t just about feasibility — its about boldness, timing, and tech that transforms. https://glance.eyesoneyecare.com
← All Global Trial Accelerators editions · Contact bioaccess®